Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

Oppenheimer analyst Les Sulewski initiates coverage on Cormedix (NASDAQ:CRMD) with a Outperform rating and announces Price Target of $15.